Download PDF
Semin Respir Crit Care Med 2013; 34(01): 067-086
DOI: 10.1055/s-0032-1333544
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Latent Tuberculosis Infection

Andrew Vernon
1   Division of Tuberculosis Elimination, Clinical Research Branch, Centers for Disease Control and Prevention (CDC/OID [Office of Infectious Diseases]/NCHHSTP [National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention]), Atlanta, Georgia
› Author Affiliations
Further Information

Publication History

Publication Date:
04 March 2013 (online)

   Permissions and Reprints

Abstract

Latent tuberculosis infection (LTBI) refers to a circumstance in which viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically. In favorable circumstances, some of these inactive bacilli resume greater metabolic activity and replication, leading to the development of active tuberculosis disease. Treatment of this condition (TLTBI) is designed to prevent (soon, or in the distant future) this progression from asymptomatic infection to symptomatic, potentially lethal, active disease. This narrative review draws upon recent reviews of LTBI and seeks particularly to include recently published or presented data that are not included in those prior reviews. Adverse effects of treatment are considered, as are the special circumstances of human immunodeficiency virus–related LTBI, drug resistance, and use of TLTBI in the context of tumor necrosis factor alpha (TNF-α) inhibition. The review describes the main studies underpinning Centers for Disease Control and Prevention recommendations on use of the new 3-month isoniazid-rifapentine regimen and points to evolving data that may support future modification of those recommendations.

Keywords

latent TB - TB preventive therapy - TB prophylaxis - isoniazid - 3HP - rifapentine

Disclaimer

The findings and conclusions in this review are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.


 

  • References

  • 1 Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15 (4) 603-622
    CrossrefPubMedGoogle Scholar
  • 2 Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-266
    PubMedGoogle Scholar
  • 3 Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37 (3) 690-711
    CrossrefPubMedGoogle Scholar
  • 4 Lincoln EM. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954; 69 (5) 682-689
    PubMedGoogle Scholar
  • 5 Esmail H, Barry III CE, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today 2012; 17 (9–10) 514-521
    CrossrefPubMedGoogle Scholar
  • 6 Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64 (6) 2062-2069
    PubMedGoogle Scholar
  • 7 Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculosis?. Annu Rev Microbiol 2010; 64: 293-311
    CrossrefPubMedGoogle Scholar
  • 8 McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence, I: The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123 (3) 445-468
    CrossrefPubMedGoogle Scholar
  • 9 McCune RM, Feldmann FM, McDermott W. Microbial persistence, II: Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966; 123 (3) 469-486
    CrossrefPubMedGoogle Scholar
  • 10 Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in sputum. Am J Respir Crit Care Med 2010; 181 (2) 174-180
    CrossrefPubMedGoogle Scholar
  • 11 Harding JS, Schreiber HA, Sandor M. Granuloma transplantation: an approach to study mycobacterium-host interactions. Front Microbiol 2011; 2: 245
    PubMedGoogle Scholar
  • 12 Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2012; 217 (3) 363-374
    CrossrefPubMedGoogle Scholar
  • 13 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282 (7) 677-686
    CrossrefPubMedGoogle Scholar
  • 14 Bennett DE, Courval JM, Onorato I , et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008; 177 (3) 348-355
    CrossrefPubMedGoogle Scholar
  • 15 Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infarction. MMWR Recc Rep 2000; 49 (No. RR-6) 1-51
    PubMedGoogle Scholar
  • 16 Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (10) (Suppl. 02) S231-S279
    PubMedGoogle Scholar
  • 17 Benator D, Bhattacharya M, Bozeman L , et al; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360 (9332) 528-534
    CrossrefPubMedGoogle Scholar
  • 18 Ji B, Truffot-Pernot C, Lacroix C , et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148 (6 Pt 1) 1541-1546
    CrossrefPubMedGoogle Scholar
  • 19 Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994; 150 (5 Pt 1) 1355-1362
    CrossrefPubMedGoogle Scholar
  • 20 Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40 (3) 552-555
    PubMedGoogle Scholar
  • 21 Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140 (5) 1189-1193
    CrossrefPubMedGoogle Scholar
  • 22 Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009; 180 (11) 1151-1157
    CrossrefPubMedGoogle Scholar
  • 23 Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2011; 184 (6) 732-737
    CrossrefPubMedGoogle Scholar
  • 24 Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next?. Int J Tuberc Lung Dis 2008; 12 (12) 1352-1364
    PubMedGoogle Scholar
  • 25 American Thoracic Society. Preventive treatment in tuberculosis: a statement by the Committee on Therapy. Am Rev Respir Dis 1965; 91: 297-298
    PubMedGoogle Scholar
  • 26 American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis: a statement by an Ad Hoc Committee. Am Rev Respir Dis 1967; 96: 558-562
    PubMedGoogle Scholar
  • 27 Ferebee SH, Mount FW, Anastasiades AA. Prophylactic effects of isoniazid on primary tuberculosis in children: a preliminary report. Am Rev Tuberc 1957; 76 (6) 942-963
    PubMedGoogle Scholar
  • 28 Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis 1962; 86: 810-822
    PubMedGoogle Scholar
  • 29 Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88: 161-175
    PubMedGoogle Scholar
  • 30 Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis 1962; 85: 821-827
    PubMedGoogle Scholar
  • 31 Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85: 490-510
    PubMedGoogle Scholar
  • 32 Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1967; 17: 29-105
    PubMedGoogle Scholar
  • 33 Comstock GW, Baum C, Snider Jr DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119 (5) 827-830
    PubMedGoogle Scholar
  • 34 Egsmose T, Ang'awa JO, Poti SJ. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 1965; 33 (3) 419-433
    PubMedGoogle Scholar
  • 35 Del Castillo H, Bautista LD, Jacinto CP, Lorenzo CE, Lapuz S, Legaspi B. Chemoprophylaxis in the Philippines: a controlled pilot study among household contacts of tuberculosis cases. Bull Quezon Institute 1965; 7: 277-290
    PubMedGoogle Scholar
  • 36 Veening GJJ. Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc 1968; 41: 169-171
    PubMedGoogle Scholar
  • 37 Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis: a Veterans Administration cooperative study XII. Chest 1978; 73 (1) 44-48
    CrossrefPubMedGoogle Scholar
  • 38 Thompson NJ. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60 (4) 555-564
    PubMedGoogle Scholar
  • 39 Snider Jr DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255 (12) 1579-1583
    CrossrefPubMedGoogle Scholar
  • 40 Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999; 3 (10) 847-850
    PubMedGoogle Scholar
  • 41 Centers for Disease Control and Prevention, American Thoracic Society, IDSA. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49 (RR-6) (RR-6, No. RR-6) 1-51
    PubMedGoogle Scholar
  • 42 Polesky A, Farber HW, Gottlieb DJ , et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154 (5) 1473-1477
    CrossrefPubMedGoogle Scholar
  • 43 Villarino ME, Ridzon R, Weismuller PC , et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155 (5) 1735-1738
    CrossrefPubMedGoogle Scholar
  • 44 Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145 (1) 36-41
    CrossrefPubMedGoogle Scholar
  • 45 Page KR, Sifakis F, Montes de Oca R , et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166 (17) 1863-1870
    CrossrefPubMedGoogle Scholar
  • 46 Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010; 14 (4) e292-e297
    PubMedGoogle Scholar
  • 47 Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis 2008; 12 (2) 160-167
    PubMedGoogle Scholar
  • 48 Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130 (6) 1712-1717
    CrossrefPubMedGoogle Scholar
  • 49 Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170 (4) 445-449
    CrossrefPubMedGoogle Scholar
  • 50 Menzies D, Long R, Trajman A , et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149 (10) 689-697
    CrossrefPubMedGoogle Scholar
  • 51 Aspler A, Long R, Trajman A , et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65 (7) 582-587
    CrossrefPubMedGoogle Scholar
  • 52 Esfahani K, Aspler A, Menzies D, Schwartzman K. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis 2011; 15 (10) 1340-1346
    CrossrefPubMedGoogle Scholar
  • 53 National Library of Medicine. Randomized clinical trial comparing 4RIF vs. 9INH for LTBI treatment-effectiveness. Registered at www.ClinicalTrials.gov as NCT00931736. Accessed April 12, 2012
    PubMedGoogle Scholar
  • 54 Ormerod LP. Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing. Arch Dis Child 1987; 62 (10) 1005-1008
    CrossrefPubMedGoogle Scholar
  • 55 Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78 (2) 169-171
    CrossrefPubMedGoogle Scholar
  • 56 Bright-Thomas R, Nandwani S, Smith J, Morris JA, Ormerod LP. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child 2010; 95 (8) 600-602
    CrossrefPubMedGoogle Scholar
  • 57 Martínez Alfaro E, Solera J, Serna E , et al. Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis [in Spanish]. Med Clin (Barc) 1998; 111 (11) 401-404
    PubMedGoogle Scholar
  • 58 Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial [in Spanish]. Enferm Infecc Microbiol Clin 2007; 25 (5) 300-304
    CrossrefPubMedGoogle Scholar
  • 59 Spyridis NP, Spyridis PG, Gelesme A , et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45 (6) 715-722
    CrossrefPubMedGoogle Scholar
  • 60 Martínez Alfaro EM, Cuadra F, Solera J , et al; The GECMEI Group. Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus [in Spanish]. Med Clin (Barc) 2000; 115 (5) 161-165
    CrossrefPubMedGoogle Scholar
  • 61 Rivero A, López-Cortés L, Castillo R , et al; Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI). Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients [in Spanish]. Enferm Infecc Microbiol Clin 2007; 25 (5) 305-310
    CrossrefPubMedGoogle Scholar
  • 62 Rivero A, López-Cortés L, Castillo R , et al; Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI). Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy [in Spanish]. Enferm Infecc Microbiol Clin 2003; 21 (6) 287-292
    CrossrefPubMedGoogle Scholar
  • 63 Whalen CC, Johnson JL, Okwera A , et al; Uganda-Case Western Reserve University Research Collaboration. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337 (12) 801-808
    CrossrefPubMedGoogle Scholar
  • 64 Martinson NA, Barnes GL, Moulton LH , et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 65 Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140 (5) 1189-1193
    CrossrefPubMedGoogle Scholar
  • 66 Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (10) (Suppl. 02) S231-S279
    PubMedGoogle Scholar
  • 67 Halsey NA, Coberly JS, Desormeaux J , et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351 (9105) 786-792
    CrossrefPubMedGoogle Scholar
  • 68 Mwinga A, Hosp M, Godfrey-Faussett P , et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12 (18) 2447-2457
    CrossrefPubMedGoogle Scholar
  • 69 Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Godfrey-Faussett P, Porter JDH. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15 (2) 215-222
    CrossrefPubMedGoogle Scholar
  • 70 Gordin F, Chaisson RE, Matts JP , et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283 (11) 1445-1450
    CrossrefPubMedGoogle Scholar
  • 71 Centers for Disease Control and Prevention (CDC). Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50 (15) 289-291
    PubMedGoogle Scholar
  • 72 Centers for Disease Control and Prevention (CDC). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50 (34) 733-735
    PubMedGoogle Scholar
  • 73 Centers for Disease Control and Prevention (CDC). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51 (44) 998-999
    PubMedGoogle Scholar
  • 74 Ijaz K, Jereb JA, Lambert LA , et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006; 42 (3) 346-355
    CrossrefPubMedGoogle Scholar
  • 75 McElroy PD, Ijaz K, Lambert LA , et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41 (8) 1125-1133
    CrossrefPubMedGoogle Scholar
  • 76 Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (31) 735-739
    PubMedGoogle Scholar
  • 77 Schechter M, Zajdenverg R, Falco G , et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006; 173 (8) 922-926
    CrossrefPubMedGoogle Scholar
  • 78 Martinson NA, Barnes GL, Moulton LH , et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365 (1) 11-20
    CrossrefPubMedGoogle Scholar
  • 79 Sterling TR, Villarino ME, Borisov AS , et al. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N Engl J Med 2011; 365 (23) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 80 Ji B, Truffot-Pernot C, Lacroix C , et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148 (6 Pt 1) 1541-1546
    CrossrefPubMedGoogle Scholar
  • 81 Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994; 150 (5 Pt 1) 1355-1362
    CrossrefPubMedGoogle Scholar
  • 82 Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999; 43 (9) 2126-2130
    PubMedGoogle Scholar
  • 83 Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005; 172 (11) 1452-1456
    CrossrefPubMedGoogle Scholar
  • 84 Kritski AL, Marques MJO, Rabahi MF , et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153 (1) 331-335
    CrossrefPubMedGoogle Scholar
  • 85 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353 (9167) 1843-1847
    CrossrefPubMedGoogle Scholar
  • 86 Sterling T, Benson C, Shang N , et al; AIDS Clinical Trials Group, Tuberculosis Trials Consortium. Tolerability among HIV-positive persons of three months of once-weekly rifapentine + INH (3HP) versus 9 months of daily INH (9H) for treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC Study 26/ACTG 5259). MOAB0302—Oral Abstract, presented at the 19th International AIDS Conference, Washington DC, July 2012. http://pag.aids2012.org/Abstracts.aspx?SID=211&AID=5981 . Accessed September 20, 2012
    PubMedGoogle Scholar
  • 87 Villarino ME, Scott N, Weis S , et al , IMPAACT, and the Tuberculosis Trials Consortium. Tolerability among children of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). Oral abstract 1323. Paper presented at: Infectious Disease Society of America (IDSA); October 20, 2012; San Diego, CA. Available at: https://idsa.confex.com/idsa/2012/ . Accessed: November 20, 2012
    Google Scholar
  • 88 Girling DJ, Hitze KL. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother 1977; 3 (2) 115-132
    PubMedGoogle Scholar
  • 89 Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5 (2) 231-249
    CrossrefPubMedGoogle Scholar
  • 90 Matteelli A, Olliaro P, Signorini L , et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis 1999; 3 (11) 1043-1046
    PubMedGoogle Scholar
  • 91 Dietze R, Teixeira L, Rocha LM , et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45 (7) 1972-1976
    CrossrefPubMedGoogle Scholar
  • 92 Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60 (48) 1650-1653
    PubMedGoogle Scholar
  • 93 Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection—United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59 (8) 224-229
    PubMedGoogle Scholar
  • 94 Evaluating the safety and effectiveness of short-course rifapentine/isoniazid for the prevention of active tuberculosis in HIV-infected individuals with latent tuberculosis infection. http://www.clinicaltrials.gov/ct2/show/NCT01404312?term=tuberculosis%2C+rifapentine%2C+actg&rank=1 . Accessed September 30, 2012
    PubMedGoogle Scholar
  • 95 Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106 (3) 357-365
    PubMedGoogle Scholar
  • 96 American Thoracic Society, National Tuberculosis and Respiratory Disease Association, Center for Disease Control. Preventive treatment of tuberculosis. Am Rev Respir Dis 1971; 104 (3) 460-463
    PubMedGoogle Scholar
  • 97 Centers for Disease Control, U.S. Dept of Health Education and Welfare. Isoniazid and liver disease: report of the ad hoc committee on isoniazid and liver disease. Am Rev Respir Dis 1971; 104: 454
    PubMedGoogle Scholar
  • 98 Kopanoff DE, Snider Jr DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117 (6) 991-1001
    PubMedGoogle Scholar
  • 99 American Thoracic Society, American Lung Association, Center for Disease Control. Preventive therapy of tuberculous infection. Am Rev Respir Dis 1974; 110 (3) 371-374
    PubMedGoogle Scholar
  • 100 Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid?. Ann Intern Med 1981; 94 (6) 808-813
    CrossrefPubMedGoogle Scholar
  • 101 Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med 1988; 4 (2) 102-109
    PubMedGoogle Scholar
  • 102 Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150 (12) 2517-2522
    CrossrefPubMedGoogle Scholar
  • 103 Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA 1986; 256 (19) 2709-2713
    CrossrefPubMedGoogle Scholar
  • 104 Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127 (12) 1051-1061
    CrossrefPubMedGoogle Scholar
  • 105 American Thoracic Society, Centers for Disease Control and Prevention. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983; 127 (6) 790-796
    PubMedGoogle Scholar
  • 106 Snider Jr DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255 (12) 1579-1583
    CrossrefPubMedGoogle Scholar
  • 107 Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993; 159 (5) 560-564
    PubMedGoogle Scholar
  • 108 Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996; 164 (6) 486-491
    PubMedGoogle Scholar
  • 109 Wu SS, Chao CS, Vargas JH , et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007; 84 (2) 173-179
    CrossrefPubMedGoogle Scholar
  • 110 Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281 (11) 1014-1018
    CrossrefPubMedGoogle Scholar
  • 111 Saukkonen JJ, Cohn DL, Jasmer RM , et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174 (8) 935-952
    CrossrefPubMedGoogle Scholar
  • 112 Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated hepatitis—New York, 1991-1993. MMWR Morb Mortal Wkly Rep 1993; 42 (28) 545-547
    PubMedGoogle Scholar
  • 113 Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167 (11) 1472-1477
    CrossrefPubMedGoogle Scholar
  • 114 Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011; 183 (3) E173-E179
    CrossrefPubMedGoogle Scholar
  • 115 Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57 (11) 799-804
    CrossrefPubMedGoogle Scholar
  • 116 Centers for Disease Control & Prevention. Treatement of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52 (RR-11) 1-77
    PubMedGoogle Scholar
  • 117 Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5 (Suppl. 03) S440-S450
    CrossrefPubMedGoogle Scholar
  • 118 Aquinas M, Allan WGL, Horsfall PA , et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. BMJ 1972; 1 (5803) 765-771
    CrossrefPubMedGoogle Scholar
  • 119 Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore: the results up to 30 months. Am Rev Respir Dis 1977; 116 (5) 807-820
    PubMedGoogle Scholar
  • 120 Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis. Ann Intern Med 1998; 129 (10) 779-786
    CrossrefPubMedGoogle Scholar
  • 121 Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health 2001; 78 (3) 550-567
    CrossrefPubMedGoogle Scholar
  • 122 Snyder DC, Paz EA, Mohle-Boetani JC, Fallstad R, Black RL, Chin DP. Tuberculosis prevention in methadone maintenance clinics: effectiveness and cost-effectiveness. Am J Respir Crit Care Med 1999; 160 (1) 178-185
    CrossrefPubMedGoogle Scholar
  • 123 Mohle-Boetani JC, Miller B, Halpern M , et al. School-based screening for tuberculous infection: a cost-benefit analysis. JAMA 1995; 274 (8) 613-619
    CrossrefPubMedGoogle Scholar
  • 124 Tan MC, Marra CA, Sadatsafavi M , et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health 2008; 11 (5) 842-852
    CrossrefPubMedGoogle Scholar
  • 125 Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med 1988; 4 (2) 102-109
    PubMedGoogle Scholar
  • 126 Aspler A, Long R, Trajman A , et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65 (7) 582-587
    CrossrefPubMedGoogle Scholar
  • 127 Esfahani K, Aspler A, Menzies D, Schwartzman K. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis 2011; 15 (10) 1340-1346
    CrossrefPubMedGoogle Scholar
  • 128 Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49 (12) 1883-1889
    CrossrefPubMedGoogle Scholar
  • 129 Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179 (11) 1055-1060
    CrossrefPubMedGoogle Scholar
  • 130 Holland DP, Sanders GD, Hamilton CD, Stout JE. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS ONE 2011; 6 (7) e22276
    CrossrefPubMedGoogle Scholar
  • 131 Chavan S, Newlands D, Smith C. A systematic review of economic evaluations of chemoprophylaxis for tuberculosis. J Trop Med 2011; 2011: 130976 DOI: 10.1155/2011/130976.
    PubMedGoogle Scholar
  • 132 Pitchenik AE, Cole C, Russell BW, Fischl MA, Spira TJ, Snider Jr DE. Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med 1984; 101 (5) 641-645
    CrossrefPubMedGoogle Scholar
  • 133 Pape JW, Jean SS, Ho JL, Hafner A, Johnson Jr WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342 (8866) 268-272
    CrossrefPubMedGoogle Scholar
  • 134 Graham NMH, Galai N, Nelson KE , et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156 (8) 889-894
    CrossrefPubMedGoogle Scholar
  • 135 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1) CD000171
    PubMedGoogle Scholar
  • 136 Hawken MP, Meme HK, Elliott LC , et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11 (7) 875-882
    CrossrefPubMedGoogle Scholar
  • 137 Fitzgerald DW, Severe P, Joseph P , et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001; 28 (3) 305-307
    CrossrefPubMedGoogle Scholar
  • 138 Gordin FM, Matts JP, Miller C , et al; Terry Beirn Community Programs for Clinical Research on AIDS. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337 (5) 315-320
    CrossrefPubMedGoogle Scholar
  • 139 Lim HJ, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials 2006; 7 (4) 172-183
    CrossrefPubMedGoogle Scholar
  • 140 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl. 01) S52-S62
    CrossrefPubMedGoogle Scholar
  • 141 Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis 2007; 11 (10) 1114-1120
    PubMedGoogle Scholar
  • 142 Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000; 4 (10) 895-903
    PubMedGoogle Scholar
  • 143 Samandari T, Agizew TB, Nyirenda S , et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9777) 1588-1598
    CrossrefPubMedGoogle Scholar
  • 144 World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland; 2011. http://www.stoptb.org/wg/tb_hiv/assets/documents/9789241500708_eng.pdf . Accessed September 30, 2012
    PubMedGoogle Scholar
  • 145 Suthar AB, Lawn SD, del Amo J , et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9 (7) e1001270 DOI: 10.1371/journal.pmed.1001270.
    CrossrefPubMedGoogle Scholar
  • 146 Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS ONE 2012; 7 (3) e34156 DOI: 10.1371/journal.pone.0034156.
    CrossrefPubMedGoogle Scholar
  • 147 Rangaka MX, Boulle A, Wilkinson RJ , et al. Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy in South Africa. Oral late breaker presented 26 July 2012 at the International AIDS Conference, Washington, DC. Abstract. http://pag.aids2012.org/Abstracts.aspx?SID=16&AID=21471 . Accessed September 30, 2012
    PubMedGoogle Scholar
  • 148 Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson Jr WD, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356 (9240) 1470-1474
    CrossrefPubMedGoogle Scholar
  • 149 Perriëns JH, St Louis ME, Mukadi YB , et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332 (12) 779-784
    CrossrefPubMedGoogle Scholar
  • 150 Create project. Available at: http://www.tbhiv-create.org/# . Accessed May 27, 2012
    PubMed
  • 151 Churchyard G, Fielding K, Lewis J , et al; on behalf of the Thibela TB Team. Community-wide isoniazid preventive therapy does not improve TB control among gold miners: the Thibela TB Study, South Africa. Abstract 149bLB; and Fielding K, Grant A, Lewis J, Hayes R, and Churchyard G. Individual-level effect of isoniazid preventive therapy on risk of TB: the Thibela TB Study. Abstract 150bLB. 19th CROI, Seattle, WA, March 2012. http://app2.capitalreach.com/esp1204/servlet/tc?c=10164&cn=retro&s=20481&&dp=player.jsp&e=16642&mediaType=slideVideo . Accessed September 20, 2012
    PubMedGoogle Scholar
  • 152 Muyoyeta M. The ZAMSTAR Study Team. Impact of ZAMSTAR interventions on prevalence of culture-positive tuberculosis; and Shanaube K; The ZAMSTAR Study Team. Impact of ZAMSTAR interventions on transmission of tuberculosis; presented at IUATLD World Lung Health Conference, Lille FR, 30 October 2011 http://uwclh.conference2web.com/content/1060 . Accessed September 20, 2012
    PubMedGoogle Scholar
  • 153 Durovni B, Saraceni V, Pacheco A , et al. Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study. 6th IAS Conference on HIV Pathogenesis and Treatment, Rome, 2011 Abstract no. WELBB02; and Durovni B, Saraceni V, Pacheco A, Cavalcante S, Cohn S, King B, Efron A, Moulton Chaisson R, Golub J, THRio study group. Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study presented at the 19th International AIDS Conference, Washington, DC; July 2012. Abstract WEPE067. http://pag.aids2012.org/abstracts.aspx?aid=13895 . Accessed September 20, 2012
    PubMedGoogle Scholar
  • 154 Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12 (5) 744-751
    CrossrefPubMedGoogle Scholar
  • 155 Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006; (2) (2, Issue 2) CD005435 DOI: 10.1002/14651858.CD005435.pub2.
    PubMedGoogle Scholar
  • 156 Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006; 10 (1) 19-23
    PubMedGoogle Scholar
  • 157 Williams K, Minkowski A, Amoabeng O , et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56 (6) 3114-3120
    CrossrefPubMedGoogle Scholar
  • 158 Diacon AH, Donald PR, Pym A , et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56 (6) 3271-3276
    CrossrefPubMedGoogle Scholar
  • 159 Holland DP, Sanders GD, Hamilton CD, Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS ONE 2012; 7 (1) e30194
    CrossrefPubMedGoogle Scholar
  • 160 Keane J, Gershon S, Wise RP , et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 161 Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53 (30) 683-686
    PubMedGoogle Scholar
  • 162 Solovic I, Sester M, Gomez-Reino JJ , et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36 (5) 1185-1206
    CrossrefPubMedGoogle Scholar
  • 163 Tortajada C, Martínez-Lacasa J, Sánchez F , et al; Tuberculosis Prevention Working Group. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?. Int J Tuberc Lung Dis 2005; 9 (3) 276-281
    PubMedGoogle Scholar
  • 164 van Hest R, Baars H, Kik S , et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 2004; 39 (4) 488-496
    CrossrefPubMedGoogle Scholar
  • 165 Leung CC, Law WS, Chang KC , et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003; 124 (6) 2112-2118
    CrossrefPubMedGoogle Scholar
  • 166 McNeill L, Allen M, Estrada C, Cook P ; McNeillL. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123 (1) 102-106
    CrossrefPubMedGoogle Scholar
  • 167 Jasmer RM, Saukkonen JJ, Blumberg HM , et al; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137 (8) 640-647
    CrossrefPubMedGoogle Scholar
  • 168 Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest 2002; 122 (4) 1292-1298
    CrossrefPubMedGoogle Scholar
  • 169 Madhi SA, Nachman S, Violari A , et al; P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365 (1) 21-31
    CrossrefPubMedGoogle Scholar
  • 170 McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. Am J Respir Crit Care Med 2000; 162 (3 Pt 1) 989-993
    CrossrefPubMedGoogle Scholar
  • 171 Zar HJ, Cotton MF, Strauss S , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334 (7585) 136
    CrossrefPubMedGoogle Scholar
  • 172 Jasmer RM, Snyder DC, Chin DP , et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 162 (5) 1648-1652
    CrossrefPubMedGoogle Scholar
  • 173 Geiter LJ. Results of a randomized controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six-months-isoniazid. Diss., Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, 1997. UMI 9730708
    Google Scholar
  • 174 Hawken MP, Meme HK, Elliott LC , et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11 (7) 875-882
    CrossrefPubMedGoogle Scholar
  • 175 Graczy KJ, O'Brien RJ, Bek E , et al. Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results of a pilot study in Poland. Am Rev Respir Dis 1991; 143: A119
    CrossrefPubMedGoogle Scholar
  • 176 TBTC Study 26 assumed a background rate of 5% TB disease in high risk persons with LTBI; the rate observed in those receiving little or no therapy was only 1.6%. TBESC Task Order 2 has reported that many associated cases have already occurred by the time the contact investigation is implemented (Reichler M et al; manuscript submitted )
    Google Scholar
  • 177 Hill AN, Becerra JE, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect 2012; 140 (10) 1862-1872
    CrossrefPubMedGoogle Scholar